Johnson & Johnson (JNJ)
J&J Sees Continued MedTech Improvement in Q1, Eyes Better 2026
Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J's total revenues.
Birch Hill Investment Advisors LLC Decreases Holdings in Johnson & Johnson $JNJ
Birch Hill Investment Advisors LLC trimmed its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 2.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 134,441 shares of the company's stock after selling 4,014 shares during the period.
First Horizon Corp Decreases Position in Johnson & Johnson $JNJ
First Horizon Corp lessened its stake in Johnson and Johnson (NYSE: JNJ) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 141,272 shares of the company's stock after selling 2,498 shares during the quarter. Johnson and Johnson makes up approximately 1.3%
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
J&J Innovative Medicine Drives Q1 Strength: Key to Long-Term Growth?
JNJ's Innovative Medicine unit posts strong Q1 growth despite Stelara hit, with key drugs and new launches positioning the segment for long-term growth.
Put $5,000 In These Dividend Giants and Earn Passive Income Every Quarter
Earned income has a ceiling. Passive income from dividend stocks operates differently: cash flows in whether markets are up or down, whether you're working or sleeping.
How to Play J&J Stock Post a Beat-and-Raise Performance in Q1
Johnson & Johnson's JNJ first-quarter results were better than expected as it beat estimates for both earnings and sales. Despite the blockbuster drug, Stelara's loss of exclusivity (LOE), the Innovative Medicines unit once again outperformed expectations as sales of most key drugs like Darzalex, Tremfya and Erleada beat estimates.
Coca-Cola vs. Johnson & Johnson: The Safest Dividend on Wall Street Might Surprise You
Coca-Cola (NYSE:KO | KO Price Prediction) closed 2025 with steady organic growth and a 63rd consecutive dividend increase, while Johnson & Johnson (NYSE:JNJ) opened 2026 with accelerating pharmaceutical momentum and its own 64-year dividend streak intact.
J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag
J&J targets double-digit growth by 2030 despite Stelara hit, banking on Innovative Medicine strength, MedTech gains and new launches.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript
Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript
What Johnson & Johnson Earnings Signal for Healthcare ETFs
With Q1 earnings season well underway, it was Johnson & Johnson (JNJ) giving investors a peek at how the broader healthcare sector might perform. The healthcare giant beat expectations on Tuesday in revenue ($24.1 billion actual versus $23.6 expected) and earnings per share ($2.70 actual versus $2.66 expected).
